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Abstract  
Background:  Syncope  in  elderly  patients  with  heart  disease  is  a  growing  problem.  Its 
aetiological  diagnosis  is  often  difficult.  We  intended  to  investigate  the  value  of  the 
electrophysiological study (EPS) in old patients with syncope and heart disease.            
Methods:  EPS was performed in 182 consecutive patients with syncope and heart disease, 
among whom 62 patients were ≥75 years old and 120 patients <75.                                       
Results: Left ventricular ejection fraction was 43.9±11.7% in patients ≥75 and 41.1±12.6% in 
patients <75. During EPS, induced sustained ventricular arrhythmias were as frequent in both 
groups (27.4% in patients ≥75 versus 27.5% in patients <75, p=0.99) whereas AV conduction 
abnormalities were more frequent in older patients (37.1% in patients ≥75 versus 18.3% in 
patients<75, p<0.005). Syncope remained unexplained in 35.5% of patients ≥75 and in 51.7% 
of patients <75 (p<0.04). ICD was more likely to be implanted in younger patients than in 
patients ≥75 years (37.5% vs 21% respectively, p<0.009). During a mean follow-up period of 
3.3±3 years,  the  4-year-survival  rate  was 66.9±6.8  % in  patients  ≥75 and 75.9±6.2 % in 
patients <75 years. The main cause of death was heart failure in both groups. The factors 
related to a worse outcome in a multivariate  analysis  were low LVEF and higher age.    
Conclusion: Complete EPS allows the identification of treatable causes in a high proportion 
of elderly patients  with syncope and heart  disease.  Yet,  the prognosis of these patients  is 
mainly  related  to  LVEF  and  age.                                     
Keywords: syncope, heart disease, electrophysiological study, elderly                                 
Introduction
Syncope  is  a  transient  loss  of  consciousness  due  to  a  global  cerebral  hypo-perfusion 
characterized  by  a  rapid  onset,  short  duration,  and  spontaneous  complete  recovery.  [1] 
Structural heart disease is a major risk factor for sudden cardiac death and overall mortality in 
patients with syncope. [1-4]  The poor outcome in these patients appears to be related to the 
severity  of  their  underlying  heart  disease  (HD)  rather  than  to  syncope  itself.  [5,6]
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Syncope is a common problem in elderly, especially in patients aged 70 years or older. [7] 
Aetiologic diagnosis is often difficult because of the frequent coexistence of several causes. 
The most common causes of syncope in the elderly are orthostatic hypotension, reflex syncope 
- especially micturition syncope and carotid sinus syndrome - and cardiac arrhythmias. [8,9]  
Cardiac origin accounts for more than 30% of the cases [1,10] whereas the syncope remains of 
unknown origin (SUO) in one out of three cases. The therapeutic goals in these patients are 
prevention of recurrences, treatment of underlying HD and reduction of cardiac mortality.    
Electrophysiology study (EPS) can help to achieve these goals in selected patients. Indeed, 
EPS has a better yield in patients with HD. [11] Yet, indications for EPS are currently scarce, 
being only recommended in patients with HD and LVEF > 35%. [1] As a consequence, it is 
performed in less than 2 % of patients with syncope [1] and very infrequently in patients with 
advanced  age.  Importantly,  the  benefit  of  a  prophylactic  implantation  of  an  implantable 
Cardioverter  defibrillator  (ICD) in  elderly  is  believed  to  be  less  [12].                  
The objectives of the present study were, therefore, to evaluate the yield of EPS in elderly 
(≥75 years)  with  HD and SUO for  the  identification  of  an  underlying  possible  cause.  In 
addition,  we  intended  to  assess  the  risk  factors  for  cardiac  death  in  these  patients  who 
underwent  EPS.                                      
Patients  and  methods                                      
All patients with HD (ischemic,  dilated cardiomyopathy) and SUO were included between 
2003 and 2013. These patients were allocated to two groups according to their age.       
Group A with 62 patients aged 75 years and above, included 48 males and 14 females.  The 
mean age was 79 ± 3.6 years. 50 of them (80.6%) presented with coronary HD and 12 (19.3) 
with dilated cardiomyopathy. The mean LVEF was 43.9% ± 11.7, 44.5±12% in patients with 
coronary HD and 40±9.5 % in patients with dilated cardiomyopathy. Patients with coronary 
HD generally  had a  previous  history  of  myocardial  infarction.  In  this  group left  anterior 
hemiblock was present in 5 patients, right bundle branch block associated (n=10 or not n=3) 
was present in 13 patients and left bundle branch block was noted in 15 patients. Group B with 
120 patients younger than 75 years old,  included 105 males and 15 females.  There was a 
tendency for a lower number of females. The mean age was 60.1 ± 11.4 years. 78 of them 
(65%) presented with coronary HD and 42 (35%) with dilated cardiomyopathy. The mean 
LVEF was 41.1% ± 12.6. In this group left anterior hemiblock was present in 11 patients, right 
bundle branch block associated (n=8 or not n=6) was present in 14 patients and left bundle 
branch  block  was  noted  in  15  patients.                                          
Data of the population are summarized in Table 1.
Table 1: Clinical data of the population
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Patients were excluded from the study if they had unstable angina, recent acute myocardial 
infarction (<1 month), recent coronary angioplasty or coronary bypass surgery (< 6 weeks), 
stenosis of the  left main coronary artery or three-vessel disease , paroxysmal second or third 
degree AV block, sustained supraventricular or ventricular arrhythmia, clinical heart failure 
not controlled by furosemide, uncontrolled electrolyte abnormalities, significant non-cardiac 
comorbidities,  received chronic amiodarone treatment,  and if  they were lost  to  follow up.
Protocol  of  the  study                                    
Personal and familial clinical history, list of drugs taken at the time of syncope and clinical 
examination were initially noted in all patients. They underwent several investigations in the 
absence of antiarrhythmic drugs after giving informed consent. These included surface ECG, 
24-hour  ambulatory  ECG  (Elatec),  transthoracic  echocardiogram,  Thallium  exercise 
scintigraphy  or coronary angiography to exclude an ischemic origin and signal averaged ECG 
(Cardionics,  QRS duration was measured by this method). The syncope was considered to be 
of unknown origin when no clear explanation was found after this conventional workup. The 
studies were performed only in patients in stable clinical and haemodynamic condition after 
treatment.  
Complete  EPS  was  performed  according  to  a  procotol  previously  reported.  [6,13,14]  A 
multichannel  oscilloscope and a programmable stimulator were used for this  purpose. The 
patients were in a fasting non sedated state and informed and written consent was obtained. 
All antiarrhythmic drugs, digoxin and drugs having an effect on cardiac electrophysiological 
properties  were  stopped  since  at  least  5  half-lives.  Most  of  the  patients  received  ACE 
inhibitors.
The electrophysiological  protocol  included assessment  of sinoatrial  conduction  time,  sinus 
node recovery time, atrioventricular conduction using measurement of AH, HV intervals and 
intraatrial conduction time, and atrial pacing at progressively faster rates until atrioventricular 
block  occurred.  Programmed  atrial  stimulation  with  1.8  ms  rectangular  pulses  at  twice 
diastolic threshold was systematically performed during sinus rhythm and atrial pacing at two 
cycle  lengths,  600 and 400 ms.  One (S2)  and then second premature  stimulus  (S3)  were 
delivered.  Right ventricular pacing was performed at an incremental rate up to 200 beats/min 
or till ventricular refractoriness. Programmed right ventricular premature stimulation using a 
single premature ventricular extrastimulus (S2) and double ventricular extrastimuli (S2 and 
S3) were introduced during sinus rhythm and during paced cycle lengths (600 and 400 ms), at 
the right ventricular apex initially and subsequently at the right ventricular outflow tract. A 
third extrastimulus was added if a sustained ventricular  tachycardia or fibrillation was not 
induced.  Triple  extrastimuli  (S2, S3, S4) were introduced during sinus rhythm and during 
paced cycle lengths (600 and 400 ms) at the right ventricular outflow tract and the apex. Short 
coupling intervals (< 200 ms) were not used in the present study. Interruption of the induced 
VT was initially attempted with different protocols of anti-tachycardia pacing, followed by 
cardioversion. If the study remained negative, the protocol was repeated after isoproterenol 
infusion : a dose of 2 to 4 μg /min was administered to decrease the sinus cycle length by at  
least  15% and  the  infusion  was  continued  until  the  completion  of  atrial  and  ventricular 
stimulation for 15 to 25 minutes. [13,14] Arterial blood pressure was continuously monitored 
by an external  sphygmomanometer  (Baxter,  Japan).  Carotid  sinus massage was performed 
except  in  patients  with  known  carotid  atheroma.                                 
Abnormal  electrophysiological  findings  were  categorized  as  sinus  node  dysfunction, 
conduction  disturbances,  hypervagotonia,  inducible  supraventricular  tachyarrhythmias 
(SVTA), or inducible ventricular tachyarrhythmia (VT) according to the following diagnostic 
criteria :
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a. Sinus node dysfunction was considered as present if the corrected sinus node recovery time 
(sinus  recovery  time  -  mean  sinus  cycle  length)  was  >  550  ms.                   
b. Conduction disturbances were considered as present, if AV Wenckebach block occurred at 
a pacing rate of < 90 bpm, or the HV interval was > 60 ms in the case of RBBB, > 70 ms in 
the case of LBBB or if the His bundle potential duration was > 40 ms, or a split His bundle 
potential was recorded in control state, and if infrahisian second degree AV block occurred at 
a  pacing  rate  less  than  150  bpm.                                   
c.  Carotid  sinus  hypersensitivity  was  present  if  right  and then  left  carotid  sinus  massage 
performed in supine position at the beginning of electrophysiological study, produced asystole 
with  an  RR  interval  of  >  3000  ms.                                
d.  Inducible  SVT  was  defined  as  a  sustained  (>  3  min),  spontaneously  terminating  but 
reproducible or permanent SVT, provokng a drop of arterial blood pressure and symptoms 
similar to spontaneous dizziness, which could be a paroxysmal junctional tachycardia or an 
atrial tachyarrhythmia (atrial fibrillation, flutter or fibrillation). The induction of a relatively 
slow atrial fibrillation without symptoms or changes in blood pressure was considered as non-
pathological. When a sustained ventricular tachycardia also was induced, the presumed cause 
for syncope was categorized in ventricular tachyarrhythmias.                                 
e. Inducible ventricular tachyarrhythmia were categorized into 1) monomorphic VT (< 270 
bpm) lasting more than 30 sec or requiring termination because of haemodynamic intolerance, 
or lasting between 10 and 30 seconds and responsible for  syncope 2) ventricular flutter (>270 
bpm) or ventricular fibrillation requiring cardioversion to stop it.
Follow-up
A pace  maker  was  implanted  in  patients  in  whom syncope  was  attributed  to  conduction 
disturbances.  In  those  with  inducible  VT and  conduction  disturbances,  a  pacemaker  or  a 
defibrillator  was implanted  depending on the 1 year  expected survival  -  patients  with life 
expectancies shorter than one year being implanted with pacemakers rather than defibrillators. 
The total cardiac deaths were deaths related to heart failure and sudden deaths. Sudden death 
was defined as an unexpected death from a cardiac cause within a short time period (< 1 
hour);  deaths  in  relationship  with  the  development  of  a  spontaneous  sustained  VT were 
classified as sudden deaths. Most of deaths occurred in our hospital; for those who died at 
home or in another hospital, we contacted both the last doctor who saw the patient and the 
family  in  order  to  classify  the  cause of  death.                                         
Statistical  analysis                                   
Continuous variables were expressed as mean ± standard deviation and categorical variables 
as  percentages.  Differences  in  continuous  and  categorical  variables  were  evaluated  with 
unpaired t test and chi square test respectively.  Survival probabilities were calculated using 
Kaplan Meier product-limit method and compared by log-rank test. Variables associated with 
survival  were  then  evaluated  with  Cox  survival  analysis.  Age,  gender  and  all  variables 
associated with a p-value <0.20 on univariable analysis were considered as candidate variables 
in  the  multivariable  models.  Backward  selection  was  performed  to  identify  variables 
independently  associated  with  survival.  These  Cox  models  were  performed  in  the  whole 
population  and  in  subsets  of  the  population  according  to  age.  All  statistical  tests  were 
performed using SPSS 21.0 for Windows. A p value < 0.05 was considered as significant.
Results
Results  of  electrophysiology  study (Table  2)                                    
A sustained monomorphic VT < 270 bpm or syncopal non-sustained VT (frequency from 220 
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to 240 bpm) was induced in 14/62 (22.6%) group A patients and in 25/120 (20.8%) group B 
patients but the difference was not statistically significant. Ventricular flutter or fibrillation 
was induced in 3/62 group A patients (4.8%) and in 8/120 (6.7%) group B patients (NS). 
Conduction abnormalities were significantly higher in the group A (23/62 patients, 37.1%) 
compared to group B (22/120, 18.3%, p < 0.005). Three group A patients and 4 group B 
patients had both conduction abnormalities and inducible VT. Atrial tachyarrhythmia (atrial 
tachycardia or paroxysmal junctional tachycardia) with a rapid ventricular rate (>130 bpm) 
was induced in 5 of 62 (8.1%) group A patients and in 8 of 120 (6.7%) group B patients (NS).  
The electrophysiological study remained negative in 62 of 120 (51.2%) group B patients and 
in 22 of 62 (35.5%) group A patients (p < 0.04).
Table 2: EPS results and device therapy 
Follow-up of the patients  (Tables 2, 3)                                                              
During a mean follow up of 3.3 ± 3 years, 35 cardiovascular deaths occurred (29 in hospital 
and 6 at home).  Non cardiovascular deaths occurred in hospital in 7 patients. A pacemaker 
was implanted  in  16 of  62 (25.8%) group A patients  and in  13 of  120 (10.8%) group B 
patients (p<0.009). In remaining patients with conduction abnormalities ICD implantation was 
preferred either because a ventricular tachycardia was induced (n= 3 in group A, n= 4 in group 
B) or because left ventricular ejection was < 35%.  Supraventricular tachycardia ablation was 
performed in 2 group A patients and none of group B patients (p<0.05).  ICD implantation 
was significantly more frequent in group B (37.5%) compared to group A (21%) (p<0.009), 
conforming to the present recommendations.  In group A, 4 patients refused ICD due to their 
age, 4 patients had an ICD implanted with a negative EPS but a low LVEF and 1 patient  
refused a pacemaker. 
Table 3: Events during follow-up according to age
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In group A, 8 patients among 13 implanted with an ICD presented an arrhythmic event at 
follow-up, 2 with a negative EPS and 6 with a positive EPS. All of them had ischemic heart  
disease and the LVEF was lower than 35% in 6 patients and higher than 35% in two patients. 
Two patients with dilated cardiomyopathy and a positive EPS, implanted with an ICD did not 
show any arrhythmic  event  on the  same follow-up period as  3 patients  with  an ischemic 
cardiomyopathy and positive EPS. In elderly patients implanted with an ICD, 61.5 % had 
appropriate shocks and almost 63 % of patients having had an appropriate shock died of heart 
failure within 8 months to 7 years. The mean survival after ICD implantation was 4.5 years in 
elderly.
In group B, implantation of an ICD was performed when the LVEF < 35% as it is actually  
recommended, or when the EPS was positive.  The death rate was significantly higher in the 
group A, (29 of 62) (47%) compared to the group B (16 of 120) (13 %) (p< 0.01). In both 
groups the major cause of death was cardiovascular but there was significantly higher rate of 
non cardiovascular mortality in the group A. There was one sudden death in group A: the 
patient presented a positive EPS, but was refused the implantation of the ICD due to a poor 
general state. There was also one sudden death in the group B, the patient had a negative EPS 
and a LVEF > 40%.  Two patients  in group A underwent a  SVT ablation.  There was no 
recurrence  of syncope at  follow-up in both groups.                                      
Analysis  of the factors associated with events                                           
In a univariate analysis the survival curves of both groups showed a significant correlation 
between  cardiac  mortality  and inducible  VT at  EPS.  (Figures  1 and  2).  Low LVEF and 
inducible VT at EPS were associated with a poor prognosis in group A and B (Figures 3, 4). 
In a multivariate analysis, only a low LVEF and an older age were significantly correlated to a 
worse outcome in both groups. (Table 4)
Figure 1: Survival in group A with and without inducible VT
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Figure 2: Survival in group B with and without inducible VT
Figure 3: Survival in group A according to the LVEF and inducible VT
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Figure 4: Survival in group B according to the LVEF and inducible VT
Table 4: Multivariate analysis in each group
Discussion
In the large randomized clinical trials that evaluated the benefit of ICD, elderly were poorly 
represented. The mean age of the patients included in the three major ICD trials were less than 
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65 (62±9 years in the MADIT trial, 64±10 in the MADIT II trial and 60±9 years in the SCD-
HeFT trial). In addition, in the Multicenter Unsustained Tachycardia (MUST) Trial, median 
age of patients treated with electrophysiologically guided therapy was 67 years (IQR 60-72 
years). [15-18]  The current knowledge regarding ICD treatment effect in elderly is mostly 
based on some sub-studies  and meta-analysis.  [21]                                      
In the present study, as in previously published reports, [12,19,20]  we observed higher rate of 
mortality in elderly patients compared to younger patients with syncope and HD. Heart failure 
was the main cause of mortality in both groups but a higher non-cardiovascular mortality rate 
was observed in elderly patients.  The EPS helped identify a potential origin for the syncope in 
more than 60% of the patients ≥ 75 years old. Inducible VT was more frequent in patients with 
a  low LVEF. [22] The results  led to a  higher  number of PM implantation in this  elderly 
population and to some ICD implantations. In our study ICD implantation was performed in 
elderly patients according to the expected survival. As a result, median survival in elderly ICD 
recipients was greater than 4 years [19,23,24].  Patients ≥ 80 years of age who meet current 
indications for ICD implantation were already reported to live long enough to warrant device 
implantation in most cases. [24] In contrast, those with an EF ≤ 20% were reported to have 
markedly elevated 1-year mortality without increased appropriate ICD therapy, thus reducing 
the net benefit of device implantation in this population. [24] Yet, based on previous reports 
and on our results, despite the presence of competing non-cardiovascular causes of deaths, the 
prognosis of selected elderly patients appears good enough to warrant ICD implantation in 
appropriate cases. We believe that ICD implantation should be encouraged in elderly patients 
with  SUO,  heart  disease  and  positive  EPS  according  to  their  expected  1-year  survival. 
Importantly,  special attention has to be paid to the evaluation of elderly with low ejection 
fraction given their high probability of death - either cardiac or non-cardiac.                  
If  the  treatment  of  underlying  VT  is  troublesome  in  elderly  patients,  the  treatment  of 
conduction  abnormalities  or  supraventricular  tachycardia  can  be quite  easily  performed in 
elderly. As we diagnosed conduction abnormalities in a third of patients >75 undergoing EPS, 
the diagnostic yield of EPS in this elderly population appears very high. This aspect further 
encourages  performing  EPS  in  elderly  patients  with  SUO  and  heart  disease.        
Limitations  of  the  study                                         
The number of patients is small. The study is retrospective and recruitment over a 10-year 
period during which the management of some situations changed. Head-up tilt test was only 
performed when the medical history suggested a vaso-vagal origin. The proportion of female 
gender was higher in patients >75 years, which was expected given the better female survival 
in  our country.  Brain CT,  EEG, or  Carotid  Doppler  were not  performed in elderly  group 
resulting in possible underdiagnosis of other syncope etiology.                                 
Conclusions
EPS in elderly patients with structural heart disease and SUO helps to identify syncope cause. 
As we observed a good survival  of selected  elderly  patients  in  whom VT was diagnosed 
during EPS, ICD implantation should be encouraged in elderly according to their expected 1-
year survival. Importantly, special attention has to be paid to the evaluation of elderly with 
low ejection fraction given their high probability of death - either cardiac or non-cardiac.  
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